8-K: Lipocine Announces Positive Topline Results for Oral Brexanolone in Pivotal Study

Lipocine's oral brexanolone, LPCN 1154, demonstrated bioequivalence to intravenous brexanolone in a pivotal pharmacokinetic study, supporting a planned NDA submission.

Summary

• Lipocine announced positive topline results from a pivotal pharmacokinetic study for LPCN 1154, an oral formulation of brexanolone, intended for the treatment of postpartum depression (PPD).
• The study compared LPCN 1154 to intravenous brexanolone (IV90) and demonstrated bioequivalence, meaning the drug exposure levels were similar between the two formulations.
• The U.S. Food and Drug Administration (FDA) has agreed with Lipocine's proposal for a 505(b)(2) New Drug Application (NDA) filing based on this single pivotal PK bridging study.
• The study was an open-label, randomized, crossover study involving 24 healthy postmenopausal women.
• The primary objective was to compare the pharmacokinetics (PK) of a multi-dose regimen of oral LPCN 1154 to IV infusion brexanolone.
• The results showed that the Geometric Mean Ratios (GMR) and 90% confidence intervals (CIs) for key measures of drug exposure (Cmax, AUC0-, and AUC0-t) fell within the 80% to 125% range, meeting the FDA's bioequivalence criteria.
• LPCN 1154 also showed a higher geometric mean trough concentration (Ctrough) compared to IV brexanolone.
• The treatment was well-tolerated, with no serious adverse events reported and only mild to moderate side effects such as headache and fatigue.
• Lipocine is targeting NDA submission by the end of the fourth quarter of 2024.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial results and a clear path to regulatory submission, indicating a strong positive sentiment.

Positives

• The study successfully demonstrated bioequivalence between oral LPCN 1154 and intravenous brexanolone, a key requirement for regulatory approval.
• The higher trough concentration of LPCN 1154 compared to IV brexanolone could potentially offer therapeutic advantages.
• The treatment was well-tolerated with no serious adverse events, indicating a favorable safety profile.
• The FDA has agreed to a 505(b)(2) NDA filing based on this single pivotal PK bridging study, streamlining the approval process.
• The company is on track to submit the NDA by the end of the fourth quarter of 2024.

Negatives

• The study was conducted on a small sample of 24 postmenopausal women, which may limit the generalizability of the results to the broader population of women with PPD.
• The study was an open-label design, which could introduce bias into the results.

Risks

• The NDA submission is targeted for the end of the fourth quarter of 2024, and any delays could impact the timeline for regulatory approval.
• The FDA review process could result in unexpected requests for additional data or studies.
• The commercial success of LPCN 1154 will depend on market acceptance and competition from other treatments for PPD.

Future Outlook

Lipocine is targeting NDA submission for LPCN 1154 by the end of the fourth quarter of 2024.

Management Comments

• The Company announced positive topline study results demonstrating bioequivalence of LPCN 1154 to IV brexanolone in an NDA enabling pivotal pharmacokinetic study.

Industry Context

This announcement is significant as it represents a potential oral alternative to the currently available intravenous brexanolone for postpartum depression, which could offer a more convenient treatment option for patients.

Comparison to Industry Standards

• The study's bioequivalence results are compared to the FDA's established criteria, which require Geometric Mean Ratios (GMR) and 90% confidence intervals (CIs) for key measures of drug exposure to fall within 80% to 125%.
• The reference product used in the study was the approved intravenous brexanolone, which is the current standard of care for PPD.
• The study design and endpoints are consistent with industry standards for pharmacokinetic bridging studies.

Stakeholder Impact

• Shareholders will likely view the positive study results favorably, potentially leading to an increase in stock value.
• Patients with postpartum depression may benefit from a more convenient oral treatment option.
• Healthcare providers will have a new treatment option to consider for their patients.

Next Steps

• Lipocine will proceed with the preparation and submission of the New Drug Application (NDA) to the FDA.
• The company will continue to monitor the safety and efficacy of LPCN 1154.

Key Dates

Keywords

LPCN 1154, brexanolone, postpartum depression, PPD, bioequivalence, pharmacokinetics, NDA, FDA, clinical trial